Hightower Clinical | Oklahoma City, OK
Status and phase
Conditions
Treatments
About
This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-Hodgkin's lymphoma [NHL]).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Inclusion Criteria Specific to Cohorts A1 and A2
Inclusion Criteria Specific to Cohort B
Inclusion Criteria Specific to Cohort C
Inclusion Criteria Specific to Cohort D
Inclusion Criteria Specific to Cohort E
Exclusion criteria
Exclusion Criteria Specific to Cohorts D and E
Primary purpose
Allocation
Interventional model
Masking
345 participants in 5 patient groups
Loading...
Central trial contact
Reference Study ID Number: ML43389 https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal